This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access Genotropin® (somatropin, rbe) prescribing information and adverse event reporting can be found at the bottom of the page.

Treatment in young adults and adolescents

Continued growth hormone (GH) treatment can have benefits beyond final height 1-11

Not all adolescent patients will need to continue GH therapy after reaching final height. However, some adult patients with growth hormone deficiency (GHD) may see benefits by continuing GH therapy beyond final height: 12

  • Proven maturation of body composition

Continuing GH therapy after final height increases lean body mass and decreases fat mass 2-4

  • Increase in bone mass and density

Continuing GH therapy induces a significant progression towards peak bone mass  5,6

Continuation of GH therapy beyond final height helps ensure that childhood-onset GHD patients achieve full somatic development 1-11

Guidance for Patient Transition to Adult Treatment13,14

Children with GH deficiency should be treated as outlined in the NICE Technology Appraisal Guidance 188.13

When linear growth has been achieved with a growth rate < 2 cm/year, GH treatment should be stopped for 2–3 months, and then GH status should be re-assessed.

As outlined in the NICE Technology Appraisal Guidance TA6414 GH treatment at adult doses should be re-started only in those satisfying the biochemical criteria for severe GH deficiency (defined as a peak GH response of less than 9 mU/litre (3 ng/ml) during an insulin tolerance test or a cross-validated GH threshold in an equivalent test), and continued until adult peak bone mass has been achieved (normally around 25 years of age).

After adult peak bone mass has been achieved, the decision to continue growth hormone treatment should be based on all the specified criteria for adult growth hormone replacement therapy .

Explore more

Homecare

Pfizer offers a range of homecare and patient support services to Genotropin patients

Learn more

Endocrine helpline

Our dedicated nurse team are on hand to support patients being treated with Genotropin and healthcare professionals who have Genotropin patients

Contact the team


​​​References
  1. Clayton, P., et al, 2007. Growth Hormone & IGF Research, 17(5), pp.369-382.
  2. Vahl, N., et al, 2000. The Journal of Clinical Endocrinology & Metabolism, 85(5), pp.1874-1881.
  3. Attanasio, A.F., et al, 2004. The Journal of Clinical Endocrinology & Metabolism, 89(10), pp.4857-4862.
  4. Carroll, P.V., et al, 1998. The Journal of Clinical Endocrinology & Metabolism, 83(2), pp.382-395.
  5. Drake, W.M., et al, 2003. The Journal of Clinical Endocrinology & Metabolism, 88(4), pp.1658-1663.
  6. Shalet, S.M., et al, 2003. The Journal of Clinical Endocrinology & Metabolism, 88(9), pp.4124-4129.
  7. Underwood, L.E., Attie, K.M., Baptista, J. and Genentech Collaborative Study Group, 2003. The Journal of Clinical Endocrinology & Metabolism, 88(11), pp.5273-5280.
  8. Johannsson, G. and Ohlsson, C., 1998. Bailliere's clinical endocrinology and metabolism, 12(2), pp.233-250.
  9. Nørrelund, H., et al, 2000. The Journal of Clinical Endocrinology & Metabolism, 85(5), pp.1912-1917.
  10. Fors, H., et al, 2001. Clinical endocrinology, 55(5), pp.617-624.
  11. Mauras, N., et al, 2005. The Journal of Clinical Endocrinology & Metabolism, 90(7), pp.3946-3955.
  12. Thomas, J.D. and Monson, J.P., 2009. European Journal of Endocrinology, 161(suppl_1), pp.S97-S106.
  13. NICE Guideline [TA188]. Human growth hormone (somatropin) for the treatment of growth failure in children. Available here
  14. NICE Guideline [TA64]. Human growth hormone (somatropin) in adults with growth hormone deficiency. Available here
PP-GEN-GBR-0752. March 2021

The Genotropin Delivery portfolio

Learn more about the 3 devices available for Genotropin patients

Learn more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No